Avidity Biosciences, Inc. (RNA)

25.96 -0.37 (-1.40%) As of 11:01AM EDT. Market open.

Avidity Biosciences, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 253

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Troy Edward Wilson J.D., Ph.D.	Co-Founder & Independent Chairman	70k	N/A	1969
Ms. Sarah Boyce	President, CEO & Director	998.88k	1.16M	1972
Mr. Michael F. MacLean	Chief Financial & Chief Business Officer	674.74k	N/A	1966
Dr. W. Michael F. Flanagan Ph.D.	Chief Scientific & Technical Officer	675.22k	N/A	1963
Ms. Teresa McCarthy	Chief Human Resources Officer	628.79k	N/A	1964
Dr. Arthur A. Levin Ph.D.	Distinguished Scientist, Strategic Leader & Director	304.69k	433.87k	1954
Mr. Eric B. Mosbrooker	Chief Strategy Officer	45k	N/A	1967
Prof. Mark E. Davis Ph.D.	Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers	N/A	N/A	N/A
Dr. Frank P. McCormick Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	1950
Mr. Geoffrey M. Grande C.F.A.	VP of Investor Relation & Corporate Communication	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Corporate Governance

Avidity Biosciences, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.